PROTHENA CORP PUBLIC LTD CO (PRTA)
Data as of , from SEC Form 4 filings.
See up to 3 months of PRTA. The 7-day demo opens the 1M and 3M ranges and puts PRTA on your watchlist.
Start 7-day demoLatest PRTA insider trades
About PROTHENA CORP PUBLIC LTD CO (PRTA)
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
- DUBLIN 2, L2
- 67
- 2012
- XNAS
PRTA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 10 | 795,000 | $6.84M |
| Open-market sale | 2 | 16,048 | $136K |
| Option exercise | 12 | 672,000 | |
| Tax withholding / forfeiture | 3 | 11,659 | |
| Bona-fide gift | 3 | 1,215,106 | |
| Derivative transaction | 6 | 325,800 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PRTA insider transactions (Form 4)
4849 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 125,000 | $8.40 footnote F1 | $1.05M | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 90,000 | $8.57 footnote F2 | $771K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 100,000 | $8.57 footnote F1 | $857K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 162,000 | $8.68 footnote F1 | $1.41M | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 103,500 | $8.60 footnote F1 | $890K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 100,000 | $8.43 footnote F1 | $843K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 27,000 | $9.47 footnote F1 | $256K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $8.79 footnote F1 | $439K | |
| ||||||
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 336,000 | $0.00 | - | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 627,553 | $0.00 | - | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 251,553 | $0.00 | - | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 34,000 | $8.62 footnote F1 | $293K | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 3,500 | $8.62 footnote F1 | $30K | |
| ||||||
| Wagner M. Zago - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 51,000 | $8.56 | $437K | |
| Wagner M. Zago - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 51,000 | - footnote F1 | - | |
| Wagner M. Zago - Officer | Option exercise | Restricted Stock Units | 51,000 | $0.00 | - | |
| ||||||
 Karin L. Walker - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 15,000 | $8.56 | $128K | |
| Karin L. Walker - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 15,000 | - footnote F1 | - | |
| Karin L. Walker - Officer | Option exercise | Restricted Stock Units | 15,000 | $0.00 | - | |
| ||||||
| Chad J. Swanson - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 40,800 | $8.56 | $349K | |
| Chad J. Swanson - Officer | Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 3,467 | $8.56 | $30K | |
| Chad J. Swanson - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 51,000 | - footnote F1 | - | |
| Chad J. Swanson - Officer | Option exercise | Restricted Stock Units | 51,000 | $0.00 | - | |
| ||||||
| Brandon S. Smith - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 78,000 | $8.56 | $668K | |
| Brandon S. Smith - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 78,000 | - footnote F1 | - | |
| Brandon S. Smith - Officer | Option exercise | Restricted Stock Units | 78,000 | $0.00 | - | |
| ||||||
 Tran Nguyen - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 57,000 | $8.56 | $488K | |
| Tran Nguyen - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 57,000 | - footnote F1 | - | |
| Tran Nguyen - Officer | Option exercise | Restricted Stock Units | 57,000 | $0.00 | - | |
| ||||||
| Gene G. Kinney - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 84,000 | $8.56 | $719K | |
| Gene G. Kinney - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 84,000 | - footnote F1 | - | |
| Gene G. Kinney - Officer | Option exercise | Restricted Stock Units | 84,000 | $0.00 | - | |
| ||||||
 Anne Evans Kingston - Officer | Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 3,498 | $8.56 | $30K | |
| Anne Evans Kingston - Officer | Open-market sale | Ordinary Shares, par value $0.01 per share | 7,662 | $8.47 footnote F2 | $65K | |
| ||||||
| Michael John Isaacs - Officer | Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 4,694 | $8.56 | $40K | |
| Michael John Isaacs - Officer | Open-market sale | Ordinary Shares, par value $0.01 per share | 8,386 | $8.47 footnote F2 | $71K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 20,000 | $7.90 footnote F1 | $158K | |
| ||||||
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 325,000 | $0.00 | - | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 125,000 | $8.17 footnote F1 | $1.02M | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $9.31 footnote F1 | $465K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $9.43 footnote F1 | $471K | |
| ||||||
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 100,000 | $9.81 footnote F1 | $981K | |
| ||||||
| Daniel G. Welch | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
 Dennis J. Selkoe | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Lars Ekman | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
 William H. Dunn Jr. | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Shane Cooke | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Richard T. Collier | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
Item 5.02, 9.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Item 7.01, 8.01, 9.01
Recent PRTA Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
PRTA insider trading FAQ
What is the latest insider trade for PRTA?
PROTHENA CORP PUBLIC LTD CO (PRTA) had 18 insider filings in the last 90 days, with the most recent on 2026-10-09. The full record for PRTA runs to 49 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PRTA stock?
10 insider purchases of PRTA were filed in the last 90 days, totaling $6.84M.
How many insiders are selling PRTA stock?
2 insider sales of PRTA were filed in the last 90 days, totaling $136K.
Where can I see PRTA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PRTA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
$PRVAPrivia Health Group, Inc.
$PSNLPersonalis, Inc.
$PSTVPLUS THERAPEUTICS, INC.
$PSTXPoseida Therapeutics, Inc.
$PTCTPTC THERAPEUTICS, INC.
$PTGXProtagonist Therapeutics, Inc
$PTHSPelthos Therapeutics Inc.
$PTIXProtagenic Therapeutics, Inc.\new
$PTNPALATIN TECHNOLOGIES INC
$PTPIPetros Pharmaceuticals, Inc.
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
- - William P. Scully view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PRTA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PRTA with a 7-day demo
- PRTA on your watchlist
- Every PRTA Form 4 filing on record
- Up to 3 months of PRTA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.